The company is also pausing research for several treatments it has been developing for another form of muscular dystrophy.

Quarterly pharmaceutical sales surpassed $15 billion for the first time as strong performance from J&J's cancer medicines offset slumping Stelara sales.

Vinay Prasad overruled other reviewers for a third time in recent months in clearing only narrow use of Moderna's vaccine in ...

Anselamimab, which AstraZeneca acquired via Caelum Biosciences, missed its primary goal in two late-stage trials, but appeared to have some benefit in a subgroup of patients.

States representing about 84% of Medicaid beneficiaries are participating in an initiative that enables the U.S. government ...